A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ

Urology

Volumn 78, Issue 4, 2011, Pages 832-837

  Bex, Axel ^a   Blank, Christian ^a   Meinhardt, Wim ^a   Van Tinteren, Harm ^a   Horenblas, Simon ^a   Haanen, John ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATIONAL STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROBABILITY; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 80053907517     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.05.034     Document Type: Article

References (29)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 22 2009 3584 3590
2. B. Escudier, M.G. Goupil, and C. Massard Sequential therapy in renal cell carcinoma Cancer 115 10 Suppl 2009 2321 2326
3. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124
4. T.K. Choueiri, W. Xie, and C. Kollmannsberger The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 1 2011 60 66
5. C.G. Wood, and V. Margulis Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease Cancer 115 10 Suppl 2009 2355 2360
6. A. Bex, E. Jonasch, and Z. Kirkali Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials Eur Urol 58 6 2010 819 828
7. A.A. van der Veldt, M.R. Meijerink, and A.J. van den Eertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 8 2008 2431 2436
8. E.J. Abel, S.H. Culp, and N.M. Tannir Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma Eur Urol 59 1 2011 10 15
9. R.J. Motzer, M.D. Michaelson, and B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 1 2006 16 24
10. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2 2004 205 213
11. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 1989 1 10
12. A. Bex, A.A. van der Veldt, and C. Blank Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib Acta Oncol 49 4 2010 520 523
13. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134
14. P. Marzola, A. Degrassi, and L. Calderan Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma Clin Cancer Res 11 16 2005 5827 5832
15. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2001 2271 2281
16. A.A. van der Veldt, M.R. Meijerink, and A.J. van den Eertwegh Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib Br J Cancer 102 5 2010 803 809
17. P.D. Nathan, A. Vinayan, and D. Stott CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies Cancer Biol Ther 9 1 2010 15 19
18. A.D. Smith, S.N. Shah, and B.I. Rini Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy AJR Am J Roentgenol 194 6 2010 1470 1478
19. A.D. Smith, M.L. Lieber, and S.N. Shah Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR Am J Roentgenol 194 1 2010 157 165
20. R. Thiam, L.S. Fournier, and L. Trinquart Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib Ann Oncol 21 5 2010 936 941
21. S. Patil, R.A. Figlin, and T.E. Hutson Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2 2010 295 300
22. A. Bex, S. Horenblas, and W. Meinhardt The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ Eur Urol 42 6 2002 570 574
23. A. Bex, A.A. van der Veldt, and C. Blank Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery World J Urol 27 4 2009 533 539
24. J.L. Silberstein, F. Millard, and R. Mehrazin Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery BJU Int 106 9 2010 1270 1276
25. C.L. Cowey, C. Amin, and R.S. Pruthi Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 9 2010 1502 1507
26. N.J. Hellenthal, W. Underwood, and R. Penetrante Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma J Urol 184 3 2010 859 864
27. E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 25 2001 4076 4081
28. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 25 2009 4068 4075
29. T. Powles, I. Kayani, and C. Blank The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer Ann Oncol 22 5 2011 1041 1047